Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 4/20 | 0.47 |
| ▸ | FNTB | P49356 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794097 | 1.00 | TRPV1 (0.56) | TRPV1KDM4EATMPOLBFNTA | |
| SCHEMBL12635058 | 0.81 | TRPV1 (0.73) | TRPV1FNTAFNTB | |
| SCHEMBL28570841 | 0.80 | TRPV1 (0.56) | TRPV1POLB | |
| SCHEMBL13696700 | 0.79 | TRPV1 (0.46) | TRPV1KDM4EATMPOLBFNTA | |
| SCHEMBL9362596 | 0.79 | TRPV1 (0.46) | TRPV1KDM4EATMPOLBFNTA | |
| SCHEMBL11531994 | 0.79 | NAPRT (0.52) | KDM4EPOLBNPC1CASP3RAB9A | |
| SCHEMBL17165759 | 0.79 | NAPRT (0.52) | KDM4EPOLBNPC1CASP3RAB9A | |
| SCHEMBL11531991 | 0.79 | NAPRT (0.52) | KDM4EPOLBNPC1CASP3RAB9A | |
| SCHEMBL7679084 | 0.78 | SMN1; SMN2 (0.67) | KDM4EPOLBNPC1CASP3RAB9A | |
| SCHEMBL396577 | 0.78 | SMN1; SMN2 (0.67) | KDM4EPOLBNPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | claimed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | claimed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | TRPV1 8/4885KDM4E 3901/4885ATM 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.